Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
278.25 USD | +0.70% |
|
+0.39% | +18.25% |
EPS & Dividend: Alnylam Pharmaceuticals, Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Rate of return | - | - | - | - | - | - | - | - |
EPS 2 | -8.11 | -7.46 | -7.2 | -9.3 | -3.52 | -2.009 | -1.265 | 2.704 |
Distribution rate | - | - | - | - | - | - | - | - |
Reference price 2 | 115.17 | 129.97 | 169.58 | 237.65 | 191.41 | 278.25 | 278.25 | 278.25 |
Nbr of stocks (in thousands) | 111,490 | 116,181 | 119,601 | 123,028 | 125,493 | 128,981 | 128,981 | - |
Announcement Date | 06/02/20 | 11/02/21 | 10/02/22 | 23/02/23 | 15/02/24 | - | - | - |
Upcoming events: Alnylam Pharmaceuticals, Inc.
Yield (Y) | Yield (Y+1) | P/E ratio (Y) | Price to Book (Y) | EV / Sales (Y) | ||
---|---|---|---|---|---|---|
-.--% | -.--% | -137.51x | 642.01x | 15.15x | ||
0.62% | 0.71% | 68.04x | 45.21x | 17.31x | ||
2.25% | 2.7% | 22.75x | 13.32x | 8.13x | ||
3.08% | 3.26% | 22.34x | 5.22x | 4.32x | ||
3.25% | 3.41% | 43.53x | 46.84x | 7.09x | ||
3.4% | 3.48% | 15.19x | 5.91x | 3.78x | ||
3.4% | 3.57% | 12.8x | 4.83x | 3.9x | ||
3.5% | 3.67% | 16.85x | 4.94x | 4.28x | ||
2.23% | 2.36% | 26.12x | 5.23x | 4.47x | ||
2.93% | 3.12% | 33.71x | 25.45x | 6.47x | ||
Average | percentage-no-prefix | percentage-no-prefix | 12.38x | 79.90x | 7.49x | |
Weighted average by Cap. | percentage-no-prefix | percentage-no-prefix | 34.01x | 30.16x | 8.70x |
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -

MarketScreener is also available in this country: United States.
Switch edition